Improvement of digoxin oral absorption in rabbits by incorporation into solid lipid nanoparticles

Pharmazie

Volumn 65, Issue 2, 2010, Pages 110-113

  Hu, LianDong ^a   Jia, Huiqing ^a   Luo, ZhaoLiang ^a   Liu, Ci ^a   Xing, QianBin ^a  

^a HEBEI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CABROXYPROPYLMETHYL CELLULOSE CALCIUM; CELLULOSE DERIVATIVE; DIGOXIN; GLYCEROL BEHENATE; GLYCEROL STEARATE; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; STEARIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG STABILITY; EXPERIMENTAL RABBIT; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRESSURE; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRASOUND; ZETA POTENTIAL;

ANIMALS; BIOLOGICAL AVAILABILITY; CARDIOTONIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGOXIN; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; ELECTROCHEMISTRY; LIPIDS; NANOPARTICLES; PARTICLE SIZE; RABBITS; SOLUTIONS;

EID: 76149118415     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.9241     Document Type: Article

References (17)

1. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Lee YI, Kim DD, Jee JP, Lee YB,Woo JS, Yong CS, Choi HG (2009) Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. Int J Pharm 374: 66-72.
2. Brocks DR, Betageri GV (2002) Enhanced oral absorption of halofantrine enantiomers after encapsulation in a proliposomal formulation. J Pharm Pharmacol 54: 1049-1053.
3. Chen Y, Lu Y, Chen J, Lai J, Sun J, Hu F,WuW(2009) Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm 376: 53-60.
4. Hu LD, Tang X, Cui F (2004) Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 56: 1527-1535.
5. Itoh K, Matsui S, Tozuka Y, Oguchi T, Yamamoto K (2002) Improvement of physicochemical properties of N-4472. Part II: characterization of N-4472 microemulsion and the enhanced oral absorption. Int J Pharm 246: 75-83.
6. Kennedy M, Hu J, Gao P, Li L, Ali-Reynolds A, Chal B, Gupta V, Ma C, Mahajan N, Akrami A, Surapaneni SS (2008) Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol Pharm 5: 981-993.
7. Li H, Zhao X, Ma Y, Zhai G, Li L, Lou H (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133: 238-244.
8. Mehnert W, Mader K (2001) Solid lipid nanoparticles production, characterization and applications, Adv. Drug Deliv Rev 47: 165-196.
9. Müller RH, Lucks JS (1996) Arzneistoffträger aus festen Lipidteilchen, Feste Lipidnanosphären (SLN). Eur Pat 0605497.
10. Schwarz C, MehnertW(1999) Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 16: 205-213.
11. Seeballuck F, Ashford M, Driscoll C (2003) The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells. Pharm Res 20: 1085-1092.
12. Ugazio E, Cavalli R, Gasco MR (2002) Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 241: 341-344.
13. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Schiesche MZ, Oertel R, Terhaag B, Kroemer HK, Siegmund W (2000) Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68: 6-12.
14. Yang L, Geng Y, Li H, Zhang Y, You J, Chang Y (2009) Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 64: 86-89.
15. Yang S, Gursoy RN, Lambert G, Benita S (2004) Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 21: 261-270.
16. Zhang H,YaoM, Morrison RA, Chong S (2003) Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats. Arch Pharm Res 26: 768-772.
17. Zhang YC, BenetLZ(2001) The gut as a barrier to drug absorption combined role of cytochrome P450 3A and P-Glycoprotein. Clin Pharmacokinet 40: 159-168.